&#xa0;
defaultWritten evidence submitted by defaultNovartisdefault (AMR0003)defaultFocus on Antibioticsdefault1. defaultHow has antimicrobial resistance developed in the past decade?defaultMultidrug-resistant (MDR) pathogens represent one of the greatest 
defaultchallenges
default to human health
default. Antibiotic resistance is
default now
default a linked global problem, with the dissemination of successful clones of MDR bacteria 
defaultoften
default associated with the movement of people
default1
default. The excessive and/or inappropriate use of antibiotics 
defaultis
default 
defaulta 
defaultmajor ca
defaultusative factor for the local evolution of MDR bacteria that can be further exacerbated by horizontal gene transfer of resistance determinants between different bacterial species
default1
default. 
defaultThe last decade has seen the emergence of antimicrobial resistance 
defaultaffecting entire classes of antibiotics including quinolones, t
defaultetracyclines, glycopeptides, 
defaultmacrolides
default and 
defaultβ
default‐
defaultlactams including carbapenems
default2
default 
default.
defaultIn the same time period 
defaultonly 
defaultthree new antibiotics were 
defaultsuccessfully 
defaultintroduced
default to
default market
default (linezolid, daptomycin a 
defaultceftaroline)
default2
default.
default 
defaultOf great concern is that for some MDR bacteria, no active antibiotic is available, with the fear that this problem will increase over time
default1
default, 3
default. In the USA it is estimated that &gt; 15% of hea
defaultl
defaultthcare-ass
defaulto
defaultciated infections are caused by MDR bacteria, while in Europe in 2007, it was estimated that ca. 25,000 patients died with an infection caused by and infection due to MDR 
defaultbacteria
default3
default. 
default2default. defaultWhat are the gaps in our knowledge about antimicrobial resistance?defaultH
defaultos
defaultpit
defaultal based reporting of resistant
default infections has
default improved 
defaultmarkedly
default over the last decade
default. 
defaultHowever, such reporting is frequently limited to a small number of pathogens (e.g. 
defaultStaphylococcus aureus, E.coli 
defaultand
default glycopeptide-
defaultresistant enterococci) and 
defaultindications (e.g. bacteraemia) as is exemplified by the mandatory surveillance program in England
default4
default. Information 
defaultrelating to complex
default infections associated with a significant risk of antibiotic resistance, 
default(e.g. 
defaultimplant-associated infections
default)
default 
defaultis
default not generall
defaulty collected.
defaultIn the wider community 
defaultthe 
defaultpicture of in
defaultcidence, prevalence, mortality 
defaultand cost of resistance
default remains incomplete
default. 
defaultE
defaultnhanced surveillance 
defaultoutside the
default healthcare setting 
defaultwill
default also 
defaultbe 
defaultessential if we are to 
defaultmeasure and 
defaultunderstand 
defaultthe impact
default of widespread antibiotic use in domestic, agricultural and industrial settings (e.g. sewage treatment). 
default3. defaultIs there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? defaultIf not, how could this bedefault defaultrectified?defaultF
defaultor pharmaceutical companies
default, 
defaultthe development of antibiotics does not represent a
defaultn
default attractive commercial
default proposition
default when compared to new chemical entities in other areas of medicine (e.g. cardiology, respiratory medici
defaultne, rheumatology
default,
default cancer,
default chronic diseases
default). 
defaultNew approaches 
defaultand incentives 
defaultare required 
defaultto 
defaultensure continued 
defaultindustry commitment to the 
defaultdevelopment 
defaultof
default new antibiotics. These could include:
defaulta)
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultChanges to the 
defaultr
defaultegulatory environment 
default- 
defaultreduc
defaulting
default the time interval from discovery to licensi
defaultng:
default&#xa0;
defaultb)
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultChanges to a
defaultntibiotic
default pricing
default, 
defaultto reflect their value compared with other treatments (e.g. cancer drugs)
default&#xa0;
defaultc)
default&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
defaultChanges 
defaultto
default the practice of automatically restricting new antibiotics 
defaultfor
default salvage therapy. 
defaultThe use of 
defaultnew
default 
defaultantibiotics
default as
default first-line therapy 
default(
defaultor earl
defaulty
default in the treatment path
default) for serious infections 
defaultsuch as those caused by MRSA 
defaultmay
default reduce the risk of resistance and reduce healthcare associated costs
default5
default,
default6
default, 
default 
default4.default 
defaultWhat measures (including defaultbehavioraldefault change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?default defaultInfection control 
defaulthas played a critical role in
default managing 
defaultantibiotic resistance
default in clinical settings
default. 
defaultG
defaultovernment
default targets 
defaulthave
default increas
defaulted
default accountability and awareness and redu
defaultc
defaulted
default cases of MRSA and 
defaultC
default.
default 
defaultdifficile
default across
default NHS Trusts.
default 
default 
defaultHowever, 
defaultwhile highly successful, 
defaultthe scope of the
defaultse
default targets has been limited to a small number of pathogens and indications. Therefore, it is essential that
default 
defaultN
defaultational performance measures 
defaultshould be reassessed to ensure that they are appropriately targeted
default and take into account the changing environment in te
defaultrms of causative pathogens and infections where there is a high risk of antibiotic resistance.   
defaultWhile s
defaulttewardship 
defaultplays a central role
default in 
defaultreducing the risk of antibiotic resistance
default and
default superinfections, there are areas where stewardship can be improved to achieve the desired outcomes. 
defaultWhile t
defaulthe current 
defaultslogan
default “the right drug, the right dose, at 
defaultthe right time and the right duration”
default 
defaultprovides a helpful illustration of what stewardship pro
defaultgrams 
defaultshould look like, it does not include the measurement of outcomes. There is a clear need for all CCGs and hospital to have:
defaultThe measurement of outcomes needs to be undertaken by the clinical teams and 
defaultthrough 
defaultengagement with national clinical groups 
defaultin specialties such as acute medicine, emergency medicine, orthopaedics, trauma and GPs.
defaultFurthermore, t
defaulthe current stewardship initiatives 
defaultdo not
default address many fundamental issues associated with antibiotic resistance. To effectively address antibiotic resistance
default at a patient 
defaultlevel requires
default:
defaultAntibiotics are not “wonder drugs” 
defaultin the management of complex infections 
defaultbut can achieve
default a remarkably high level of success
default, 
defaultif the
default most effective antibi
defaultotics
default are
default combined with the correct surgery and
default/or
default source control of the infected site
default7
default, 
default8
default. 
defaultThere have been significant advances in diagnostic 
defaulttechniques that should be employed to identify the causative pathogens and direct antibiotic treatment more 
defaulteffectively
default9
default, 1
default0
default. The multidisciplinary team (MDT) approach is increasingly being seen as best practice in the treatment of complex infections such as 
defaultendocarditis, 
defaultprosthetic joint and vascular graft infection
default7
default. 
defaultThe education and training of healthcare professionals is critical to success in addressing antibiotic resistance to ensure they have 
defaulta good understanding of pathogenesis, antibiotic resistance 
defaultand best practices in the use of antibacterial drugs.    
defaultTher
defaulte are potential deleterious consequences of a simplistic view of antibiotic stewardship, namely
default,
default restricting the newer and more expensive antibiotics in favour of 
default“cheaper” and generic antibiotics
default for “salvage” use. These consequences 
defaultcan include 
defaultincreasing the overall treatment course
default and associated risks for
default, morbidity
default and mortality
default to the patient,
default 
defaultselecting resistant mutants
default and increasing the overall healthcare associated costs.
defaultInternational programs such as the Surv
defaultiv
defaulting Sepsis Campaign
default1
default1
default adv
defaultocate giving the most potent and broad spectrum agent(s) as initial therapy in patients with suspected sepsis and then 
defaultd
defaulte-escalating to 
defaultantimicrobials
default with a narrower spectrum
default (if appropriate), once 
defaultthe underlying pathogen, resistance patterns, and the pat
defaultient’s res
defaultponse to treatment become clear.
default This approach has been shown to deliver better outcomes in these circumstances.
default 
default5. defaultWhat global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards crossdefault-border initiatives?defaultThrough the 
defaultactivities of the British Society for Antimicrobial Chemotherapy (BSAC) and its initiative Antibiotic Action
default1
default2
default 
defaultthe UK is at the vanguard of initiatives to address antibiotic resistance.
default This forum allows multiple stakeholders to identify, discuss and address key issues in the research, regulatory and 
defaultmarket
default environments, and 
defaultis
default regenerat
defaulting 
defaultinterest in the discovery and development of new antibiotic agents.  
defaultU
defaultnder the leadership and dir
defaultection of Professor Laura Piddock, 
defaultAntibiotic Action 
defaulthas been highly proactive in reaching out to important
default individuals and organisations
default in the UK and internationally
default,
default to address the serious problem of antibiotic resistance
default. 
defaultAs a global pharmaceutical company, Novartis recognises the international dimension of the challenge of antibiotic resistance 
defaultand is greatly encourage by 
defaultthe publication of the
default Government’s AMR 
defaultStrategy 
defaultand the impetus provided by the C
defaultMO
default’s interest in the
default subject. The UK 
defaultis 
defaultidea
defaultl
defaultl
defaulty
default position
defaulted
default to assume a leading role in tackling the global threat of antimicrobial resistance. 
defaultHowever, a
defaultny changes implemented in the UK will need to be adopted internationally to maximize their impact and for progress to be ma
defaultde. 
default&#xa0;
default&#xa0;
default6. defaultWhat are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?defaultThe Government’s five ye
defaultar
default AMR
default Strategy 
defaultprovides
default a useful platform to start
default addressing some key issues in the area of antimicrobial resistance
default and 
defaultis generally balanced in its assessment of
default the challenge
default. 
default 
defaultIf delivered, t
defaulthe three strategic aims would go a significant way to address
defaulting
default the considerable c
defaulthallenges presented by antibiotic resistance
default. Novartis were pleased to note that antibiotic stewardship (subject to the caveats presented in the document above), the urgent need for the discovery and developments of new antibiotics, diagnostics and novel t
defaultherapies and approaches are core themes within the strategy. 
defaultThe Strategy recognises the importance of improving knowledge amongst healthcare professionals and the 
defaultgeneral public to try and ensure that current treatment are preserved and used appropriately
default. These statements and objectives need to go further to include the recognition that education and training of healthcare professionals 
defaultto gain a far greater understanding of pathogenesis. Moreover, the importance of changes in current practice to enhance 
defaultand 
defaultdevelop the
default role of multidisciplinary teams in managing complex infections needs to be included. 
defaultT
defaulthe Strategy
default 
defaultplaces
default s
defaultignificant obligations on industry to produce new treatments
default but w
defaultithout offering re
defaultciprocal commitments
default to improving the 
defaultrestrictive
default 
defaultcommercial environment
default.
default  
defaultT
defaulthe Government must make concrete commitments to how they plan to 
defaultanalyse
default the challenges 
defaultassociated with AMR further and translate these, in collaboration with stakeholders, into initiatives that will drive real change.  In addre
defaultssing the commercial environment, 
defaultthe High Level Steering Group must outline how it plans to address some of the key challenges which it started to identify in the Strategy.
default 
defaultThe Strategy recommends a substantial and extended research program to 
defaultbetter und
defaulterstand resistance, discover new therapies and improve surveillance of antibiotic resistance. This will clearly need new and substantial funding. With reference to the concerns about the significant obligation on 
defaultindustry inferred
default in the Strategy, will new central (Government) funding be made available?
default&#xa0;
defaultFocus ondefault Vaccines default&#xa0;default&#xa0;default&#xa0;defaultRelevant FeaturedefaultAntibioticsdefaultVaccinesdefaultTherapeutic/prophylactic
defaultMostly therapeutic
defaultMostly prophylactic
defaultCoverage and specificity
defaultBroad, indiscriminate
defaultNarrow, specific
defaultEmergence of resistance
defaultCommon
defaultUncommon
defaultSelective 
defaultpressure
defaultHigh
defaultLow
defaultTime to develop resistance
defaultShort
defaultLong
defaultDurability
defaultRestricted to the time of treatment
defaultDuration of protection persists from several months up to life-long
defaultDuration/frequency of exposure
defaultSome patients spend weeks/months on antibiotics, 
defaultwith the potential for prolonged sub-therapeutic exposure
defaultSub-optimal schedules or responses can lead to breakthrough infections
defaultCross-class impact
defaultPotential for a single antibiotic to drive plasmid-mediated resistance to multiple antibiotics across diffe
defaultrent classes
defaultImpact of the vaccine is generally restricted to a particular type of organism, although removal of nasopharyngeal carriage can allow other types of organisms to occupy the niche
defaultBeneficial herd effect
defaultNo
defaultYes
defaultPrevention of perinatal infectio
defaultns
defaultYes
defaultYes (maternal immunisation)
defaultPrevention of cancer
defaultNo
defaultYes (HBV, HPV)
defaultControl of distribution
defaultLess tightly controlled and monitored distribution (prescribed across the breadth of the health system with variable scrutiny, control and guideline 
defaultadherence
defaultGenerally distributed through the immunisation programme, and the impact closely monitored
defaultCost
defaultFew ₤s to ₤1000s
defaultFew ₤s to ₤100s
defaultAdapted from
default Mishra 
defaultet al
default 
default15
default&#xa0;default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
defaultThis represents a 93% reduction in the incidence of invasive serogroup C disease over the first 4 years after the introduction of the vaccine
default17
default 
default&#xa0;default1992default1996/1997default1998/ 1999default2004/ 2005default2010default2011/ 2012default2012defaultHib meningitis
default18
default871
default&#xa0;
default&#xa0;
default&#xa0;
default30
default&#xa0;
default&#xa0;
defaultPneumococcal meningitis
default18,19
default&#xa0;
default398*
default&#xa0;
default252*
default&#xa0;
default&lt;100**
default&#xa0;
defaultMeningococcal 
defaultdisease
default 
default20
default 
default(meningitis and septicaemia) 
default&#xa0;
default&#xa0;
default2773
default&#xa0;
default&#xa0;
default&#xa0;
default766
default&#xa0;
defaultIn the USA, a 
defaultdecrease in 87% in antibiotic resistant disease caused by vaccine serotypes
default was reported 
defaultafter the introduction of the pneumococcal conjugate vaccine
default. 
default21 
default&#xa0;
default&#xa0;defaultReferencesdefaultOctober 2013
defaultDeclaration of defaultauthors’ defaultinterestsdefaultE. David G. McIntosh
default is an employee of Novartis Vaccines, a manufacturer of vaccines
default for the prevention of bacterial infection
default.
default 
defaultMike Allen is an employee
default of Novartis Pharmaceuticals UK Ltd, a subsidiary of Novartis AG, 
defaulta company that
default develop
defaults
default and market
defaults
default antibiotics.
default&#xa0;
default&#xa0;
default&#xa0;
default